PT  - JOURNAL ARTICLE
AU  - DIRK RADES
AU  - LIESA DZIGGEL
AU  - OLIVER BLANCK
AU  - NIKLAS GEBAUER
AU  - TOBIAS BARTSCHT
AU  - STEVEN E. SCHILD
TI  - Predicting the Risk of Developing New Cerebral Lesions After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastases from Renal Cell Carcinoma
DP  - 2018 May 01
TA  - Anticancer Research
PG  - 2973--2976
VI  - 38
IP  - 5
4099  - http://ar.iiarjournals.org/content/38/5/2973.short
4100  - http://ar.iiarjournals.org/content/38/5/2973.full
SO  - Anticancer Res2018 May 01; 38
AB  - Aim: To create an instrument for estimating the risk of new brain metastases after stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) alone in patients with renal cell carcinoma (RCC). Patients and Methods: In 45 patients with 1-3 brain metastases, seven characteristics were analyzed for association with freedom from new brain metastases (age, gender, performance score, number and sites of brain metastases, extra-cerebral metastasis, interval from RCC diagnosis to SRS/FSRT). Results: Lower risk of subsequent brain lesions after RT was associated with single metastasis (p=0.043) and supratentorial involvement only (p=0.018). Scoring points were: One metastasis=1, 2-3 metastases=0, supratentorial alone=1, infratentorial with/without supratentorial=0. Scores of 0, 1 and 2 points were associated with 6-month rates of freedom from subsequent brain lesions of 25%, 74% and 92% (p=0.008). After combining groups with 1 and 2 points, 6-month rates were 25% for those with 0 points and 83% for those with 1-2 points (p=0.002). Conclusion: Two groups were identified with different risks of new brain metastases after SRS or FSRT alone. High-risk patients may benefit from additional whole-brain irradiation.